INT96581

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 2001
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 4
Disease Relevance 3.10
Pain Relevance 1.04

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (MMP2) extracellular space (MMP2) extracellular region (MMP2)
proteinaceous extracellular matrix (MMP2) plasma membrane (MMP2) nucleus (MMP2)
Anatomy Link Frequency
PSP 2
MMP2 (Homo sapiens)
Pain Link Frequency Relevance Heat
metalloproteinase 220 100.00 Very High Very High Very High
Inflammation 52 100.00 Very High Very High Very High
Snapping jaw 1 76.76 Quite High
Arthritis 6 74.76 Quite High
Potency 5 72.56 Quite High
cytokine 82 71.84 Quite High
Osteoarthritis 15 10.24 Low Low
COX-2 inhibitor 23 5.00 Very Low Very Low Very Low
chemokine 20 5.00 Very Low Very Low Very Low
rheumatoid arthritis 15 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
INFLAMMATION 62 100.00 Very High Very High Very High
Corneal Neovascularization 3 100.00 Very High Very High Very High
Herpes Simplex Virus 238 98.08 Very High Very High Very High
Infection 104 97.80 Very High Very High Very High
Burns 1 97.68 Very High Very High Very High
Hypercalcemia 17 97.60 Very High Very High Very High
Cancer 44 96.80 Very High Very High Very High
Stomach Cancer 1 90.60 High High
Fibrosarcoma 5 86.24 High High
Carcinoma 2 84.12 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Inhibition of MMP-2 and MMP-9 activities was partly prevented by the addition of 1,10 phenanthroline, a divalent metal chelator, to the amalgam conditioned buffers.
Negative_regulation (prevented) of Negative_regulation (Inhibition) of MMP-2
1) Confidence 0.57 Published 2001 Journal Biomaterials Section Abstract Doc Link 11426881 Disease Relevance 0.23 Pain Relevance 0.23
NS-398 pretreatment reduced the expression of all MMPs tested (Figures 8D-8G), with the most significant inhibition of MMP-2 and MMP-9 (Figures 8E and 8F), suggesting that KSHV induced COX-2 plays a decisive role in controlling expression of KSHV infection induced proteases.
Negative_regulation (reduced) of Negative_regulation (inhibition) of MMP-2 associated with herpes simplex virus, metalloproteinase and infection
2) Confidence 0.17 Published 2010 Journal PLoS Pathogens Section Body Doc Link PMC2820536 Disease Relevance 1.09 Pain Relevance 0.57
Agouron developed prinomastat (AG3340) [114], a MMP inhibitor with a Ki value in the picomolar range for the inhibition of MMP-2, MMP-9, MMP-13 and MMP-14, with lower activity against MMP-1 and MMP-7 [115].
Negative_regulation (inhibitor) of Negative_regulation (inhibition) of MMP-2
3) Confidence 0.12 Published 2003 Journal Arthritis Res Ther Section Body Doc Link PMC154424 Disease Relevance 0.60 Pain Relevance 0.15
Their findings clearly show that application of PSP has reduced several parameters related to CNV and/or inflammation including the downregulation of MMP-2 and MMP-9 [77].
Negative_regulation (reduced) of Negative_regulation (downregulation) of MMP-2 in PSP associated with corneal neovascularization and inflammation
4) Confidence 0.12 Published 2010 Journal Biochemistry Research International Section Body Doc Link PMC3004377 Disease Relevance 1.19 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox